🔎 Trials Near Me

Почетна › Колоректален карцином › Масачусетс › Boston

Клинички испитувања за Колоректален карцином во Boston, MA

63 студии за Колоректален карцином бараат учесници на локации во и околу Boston (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Се регрутираФаза 1
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07544589

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Се регрутираФаза 2
  • Dana-Farber Cancer Institute - Oncology Department, Boston
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06760819

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Се регрутираФаза 2
  • Boston Medical Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT05673148

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Се регрутираФаза 1
  • Exelixis Clinical Site #7, Boston
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Insitute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06625775

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

Се регрутира
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06565052

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Се регрутираФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06324357

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07578571

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Се регрутираФаза 1
  • Research Site, Boston
  • Research Site, Boston
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05877599

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Се регрутираФаза 3
  • Brigham and Women's Hospital (BWH), Boston
  • Dana-Farber Cancer Institute (DFCI), Boston
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07222800

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Се регрутираФаза 2
  • Dana-Farber Cancer Institute /ID# 270624, Boston
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT06820463

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Се регрутираФаза 1
  • Research Site, Boston
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06218914

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Се регрутираФаза 1/2
  • Tufts Medical Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06047379

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213791

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06445062

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Се регрутираФаза 1/2
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06128551

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Се регрутираФаза 1/2
  • Massachusetts General Hospital - Main Campus, Boston
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Се регрутираФаза 1
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Се регрутираФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT05786924

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Се регрутираФаза 3
  • Massachusetts General Hospital, Boston
  • Oncura Health, Boston
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT07284849

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

Се регрутира
  • Dana Farber Cancer Institute, Boston
Возраст од 18 до 50 · Сите полови · Ажурирано 11.9.2026 · NCT06202183

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Се регрутираФаза 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT04899908

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital (MG), Boston
Возраст од 18 до 99 · Сите полови · Ажурирано 1.9.2026 · NCT06983743

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Се регрутираФаза 1
  • Mass General Cancer Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 27.8.2026 · NCT07227168

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Се регрутираФаза 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 30 Years · Сите полови · Ажурирано 25.8.2026 · NCT04851119

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 24.8.2026 · NCT06586515

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients

Се регрутираНабљудувачка студија
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT05410977

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Се регрутираФаза 1/2
  • Massachusetts General Hospital Cancer Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 11.8.2026 · NCT05592626

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 30.7.2026 · NCT07094113

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
Возраст од 18 до 100 · Сите полови · Ажурирано 29.7.2026 · NCT06562192

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Се регрутираФаза 1/2
  • Massachusetts General Hospital - Dana Farber, Boston
Возраст 18 и постари · Сите полови · Ажурирано 29.7.2026 · NCT03526835

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Се регрутираФаза 1
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.7.2026 · NCT06179160

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Се регрутираФаза 1
  • Beth Israel Deaconess Medical Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.7.2026 · NCT06131840

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Се регрутираФаза 1
  • Dana-Farber/Massachusetts General Hospital, Inc, Boston
Возраст 18 и постари · Сите полови · Ажурирано 6.7.2026 · NCT07300150

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Се регрутираФаза 1
  • Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT07458347

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Се регрутираФаза 1/2
  • Massachusetts General Hospital Cancer Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 26.6.2026 · NCT06412198

BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

Се регрутира
  • Massachusetts General Hospital Cancer Center, Boston
Возраст од 18 до 80 · Сите полови · Ажурирано 23.6.2026 · NCT07162337

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Се регрутираФаза 1
  • Research Site, Boston
  • Research Site, Boston
Возраст 18 и постари · Сите полови · Ажурирано 10.6.2026 · NCT06835569

LYL273 for Patients With Relapsed or Refractory mCRC

Се регрутираФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 9.6.2026 · NCT05319314

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Се регрутираФаза 1
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 8.6.2026 · NCT06026410

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT06040541

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Се регрутираФаза 1
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 2.6.2026 · NCT06917079

Video Education With Result Dependent dIsclosure

Се регрутира
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.5.2026 · NCT05225428

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Се регрутираФаза 1/2
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 15.5.2026 · NCT05379985

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Се регрутираРана фаза 1
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 13.5.2026 · NCT07128355

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT05692024

Remote Monitoring and Symptom Management Digital Application

Се регрутира
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 28.4.2026 · NCT07553572

A Study of MGC028 in Participants With Advanced Solid Tumors

Се регрутираФаза 1
  • Mass General Brigham, Boston
  • Dana Farber/Harvard Cancer Center, Boston
Возраст 18 и постари · Сите полови · Ажурирано 27.4.2026 · NCT06723236

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Се регрутираФаза 1
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 23.4.2026 · NCT06720987

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 22.4.2026 · NCT07020221

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Се регрутираФаза 1
  • Dana Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 2.4.2026 · NCT06451497

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 27.3.2026 · NCT06395519

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Се регрутираФаза 1/2
  • Dana-Farber Cancer Institute, Boston
Возраст 18 и постари · Сите полови · Ажурирано 18.3.2026 · NCT06244771

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

Се регрутираФаза 1
  • Massachusetts General Hospital Cancer Center, Boston
Возраст од 18 до 50 · Сите полови · Ажурирано 27.2.2026 · NCT07095517

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Се регрутираФаза 4
  • Massachussets General Hospital, Boston
Возраст од 18 до 64 · Сите полови · Ажурирано 22.1.2026 · NCT04373564

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Се регрутираФаза 1/2
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 16.1.2026 · NCT02584244

Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study

Се регрутираДобредојдени се здрави волонтери
  • Codman Square Health Center, Boston
  • East Boston Neighborhood Health Center, East Boston · на 2 милји
Возраст 18 и постари · Сите полови · Ажурирано 14.11.2025 · NCT05524428

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Се регрутираФаза 1
  • Dana Farber/Partners Cancer Care Inc, Boston
Возраст 18 и постари · Сите полови · Ажурирано 15.8.2025 · NCT04429542

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Се регрутираФаза 3
  • Massachusetts General Hospital, Boston
Возраст 18 и постари · Сите полови · Ажурирано 24.4.2024 · NCT03659448

Испитувања за Колоректален карцином во други градови

Други студии во Boston

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.